Melanotan II

Melanotan II was developed in the 1980s–1990s at the University of Arizona by Victor Hruby and colleagues as part of a program to develop sunless tanning agents that could reduce UV-associated skin cancer risk. The cyclic structure and D-amino acid substitution (D-Phe at position 7) confer high metabolic stability and potency compared to endogenous α-MSH.

The compound's profound sexual arousal effects — spontaneous erections in male subjects in early trials — led to a research pivot toward sexual dysfunction, ultimately spawning PT-141 (Bremelanotide) as a more selective MC4R-targeted derivative. Melanotan II itself was not advanced through regulatory approval due to its non-selective receptor profile and cardiovascular side effects.

Despite having no approved status anywhere in the world, Melanotan II is widely used in the grey market for tanning and sexual enhancement. Researchers study it for its mechanistic insights into the melanocortin system, though its clinical development has been superseded by more selective compounds.

// MC1R AGONISM (TANNING)

Melanotan II activates MC1R on melanocytes, stimulating melanogenesis — the production of eumelanin (brown/black pigment). This produces progressive skin darkening independent of UV exposure. The tan develops over 1–2 weeks of dosing and fades over weeks after cessation.

// MC4R AGONISM (SEXUAL AROUSAL)

MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus drives the sexual arousal and erectile effects. This same pathway was exploited more selectively in the development of PT-141/Bremelanotide (FDA-approved for HSDD). MT-II's effects are faster-onset but less selective than PT-141.

// MC3R / MC5R EFFECTS

MC3R activation contributes to appetite suppression and metabolic effects. MC5R effects include exocrine gland modulation. The broad receptor engagement distinguishes MT-II from the more targeted PT-141 and explains both its broader effect profile and its less favourable side-effect profile (more nausea, facial flushing, spontaneous erections).

Early University of Arizona human trials confirmed tanning efficacy and documented spontaneous erections as an unexpected finding — directly leading to the sexual dysfunction research program. Subsequent studies established the dose-response relationship for both tanning and sexual effects.

Key safety concerns include blood pressure elevation, nausea (often severe at higher doses), and uneven tanning/hyperpigmentation. Multiple cases of new melanocytic naevi (moles) have been reported, raising theoretical melanoma risk concerns though causation is unestablished.